Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3034257 | 1.00 | PTGS2 (0.76) | PTGS2PTGS1 | |
| SCHEMBL5850192 | 0.90 | PTGS1 (0.78) | PTGS2PTGS1 | |
| SCHEMBL5848449 | 0.89 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL5848742 | 0.89 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL5850087 | 0.89 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL5848436 | 0.89 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL5849700 | 0.87 | PTGS2 (0.65) | PTGS2PTGS1 | |
| SCHEMBL28282138 | 0.86 | PTGS2 (0.79) | PTGS2PTGS1 | |
| SCHEMBL5849738 | 0.84 | PTGS2 (0.65) | PTGS2PTGS1 | |
| SCHEMBL5847947 | 0.81 | PTGS2 (0.64) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315956-A1 | METHOD OF PRODUCTION OF THE COMPOSITION OF CYCLOOXYGENASE-2 (COX-2) INHIBITORS | US Nano Food & Drug INC | 2024-09-26 | — | — | US | claimed |
| US-12059467-B2 | Low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant, preparation method thereof, and topical sustained release drug delivery formulation including same | ANHUI UNIVERSITY (CN) | 2024-08-13 | — | — | US | claimed |
| EP-4366732-A1 | METHOD OF PRODUCTION OF THE COMPOSITION OF CYCLOOXYGENASE-2 (COX-2) INHIBITORS | US Nano Food & Drug Inc (US) | 2024-05-15 | — | — | EP | claimed |
| US-20240108728-A1 | IMPROVED LOW-TOXICITY AND HIGH-EFFICIENCY ORTHOESTER MIXTURE PHARMACEUTICAL ADJUVANT, PREPARATION METHOD THEREOF, AND TOPICAL SUSTAINED RELEASE DRUG DELIVERY FORMULATION INCLUDING SAME | ANHUI UNIVERSITY (CN) | 2024-04-04 | — | — | US | claimed |
| US-20240033124-A1 | DRUG DELIVERY CONTACT LENS AND OPHTHALMIC PHARMACEUTICAL COMPOSITION | DAE WON PHARMACEUTICAL CO., LTD (KR) | 2024-02-01 | — | — | US | claimed |
| WO-2024008131-A1 | NEW USE OF SIVELESTAT | 上海汇伦医药股份有限公司 | 2024-01-11 | — | — | WO | claimed |
| EP-4275675-A1 | DRUG DELIVERY CONTACT LENS AND OPHTHALMIC PHARMACEUTICAL COMPOSITION | Dae Won Pharmaceutical Co., Ltd. (KR) | 2023-11-15 | — | — | EP | claimed |
| WO-2023281449-A1 | METHOD OF PRODUCTION OF THE COMPOSITION OF CYCLOOXYGENASE-2 (COX-2) INHIBITORS | US Nano Food & Drug INC (US) | 2023-01-12 | — | — | WO | claimed |
| WO-2022149914-A1 | DRUG DELIVERY CONTACT LENS AND OPHTHALMIC PHARMACEUTICAL COMPOSITION | 대원제약 주식회사 | 2022-07-14 | — | — | WO | claimed |
| EP-3998932-A1 | ALKALIZATION OF URINARY BLADDER WALL PRIOR TO TREATMENT WITH INTRAVESICAL HEPARIN AND ALKALINIZED LIDOCAINE TO ENHANCE RELIEF OF BLADDER PAIN SYMPTOMS | Parsons, C. Lowell (US) | 2022-05-25 | — | — | EP | claimed |
| US-7112605-B2 | Sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones, preparation method, and medical use thereof | Research Institute of Materia Medica Chinese Acadamy of Medical Sciences (CN) | 2006-09-26 | — | — | US | claimed |
| CN-122079835-A | Preparation method of eremophilone intermediate | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4735453-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735445-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-7112605-B2 | Sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones, preparation method, and medical use thereof | Research Institute of Materia Medica Chinese Acadamy of Medical Sciences (CN) | 2006-09-26 | — | — | US | disclosed |
| US-20050187278-A1 | Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors | PHARMACIA CORPORATION (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050113409-A1 | Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith | PHARMACIA CORPORATION (US) | 2005-05-26 | — | — | US | disclosed |
| WO-2005023189-A2 | METHOD OF COX-2 SELECTIVE INHIBITOR AND NITRIC OXIDE-DONATING AGENT | PHARMACIA CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20040029951-A1 | Sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones, preparation method, and medical use thereof | RESEARCH INSTITUTE OF MATERIAL MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES; | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029951-A1 | Sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones, preparation method, and medical use thereof | PTGS1, PTGS2, PTGER1 | PTGS2 2/4885PTGS1 1/4885 |
| US-20240108728-A1 | IMPROVED LOW-TOXICITY AND HIGH-EFFICIENCY ORTHOESTER MIXTURE PHARMACEUTICAL ADJUVANT, PREPARATION METHOD THEREOF, AND TOPICAL SUSTAINED RELEASE DRUG DELIVERY FORMULATION INCLUDING SAME | TLR7, PON1, MYD88 | PTGS2 336/4885PTGS1 395/4885 |
| US-20050187278-A1 | Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors | PDE2A, PDE3A, PDE3B | PTGS2 9/4885PTGS1 16/4885 |
| US-12059467-B2 | Low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant, preparation method thereof, and topical sustained release drug delivery formulation including same | TLR7, PON1, MYD88 | PTGS2 365/4885PTGS1 453/4885 |
| US-20050113409-A1 | Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith | PTGS2, NOS2, PTGES2 | PTGS2 1/4885PTGS1 4/4885 |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PTGS2 4318/4885PTGS1 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.